The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of PF-05175157 in a dose-dependent fashion in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
31
One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Pfizer Investigational Site
South Miami, Florida, United States
Modulation of carbohydrate and lipid metabolism
Time frame: 24 hours
Cmax of PF-05175157 after single oral doses
Time frame: 24 hours
Tmax of PF-05175157 after single oral doses
Time frame: 24 hours
Area under the curve (AUC) of PF-05175157 after single oral doses
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.